Patients with Eastern Cooperative Oncology Group (ECOG) performance score 0 - 1;
Patients with histologically confirmed metastatic non-small cell lung cancer and PD-L1 expression on tumor cells was evaluated;
CT examination shows measurable tumor formations according to the RECIST 1.1 criteria;
Primary lung tumor or metastasis accessible to flexible bronchoscopy;
Patients may have received surgery, adjuvant or neoadjuvant chemotherapy prior to the study if it was completed at least 12 months before relapse;
Patients informed about the purpose and course of the study and provided a written consent to participate.
You may not be if
Patients who refused to participate in the clinical trial and did not sign the informed consent form;
Men and women under the age of 18, pregnant women;
Patients belonging to a vulnerable social group;
High risk of general anesthesia, defined as American Society of Anesthesiologists (ASA) class 4 - 6;
Documented allergy to medications used during general and local anesthesia, systemic cancer treatment;
Patients previously treated with immune checkpoint inhibitors;
EGFR mutations or ALK translocations have been identified in patients;
Patients with previously diagnosed autoimmune diseases, active viral hepatitis, uncontrolled human immunodeficiency virus (HIV) infection or untreated tuberculosis;
Patients treated with immunosuppressive drugs, systemic corticosteroids, with equivalent doses of prednisolone exceeding 10 mg/day;
Patients with an increased risk of bleeding during an interventional procedure;
Acute untreated conditions that would make it impossible to perform an interventional lung procedure.
Clareo Health | The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer
